BMO Capital analyst Joanne Wuensch kept her Outperform rating and $94 price target on Medtronic after its Diabetes Analyst Meeting at ADA yesterday. The analyst cites the company’s message that it is investing in a comprehensive program to better treat diabetes patients while focusing on systems to reduce healthcare costs, having raised its market share and decreased preventable hospitalizations. Wuensch also believes that Medtronic’s Sugar IQ software is underappreciated given its ability to start providing “customizable insights to patients after just five days of data collection”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.